409. Keeping Death at Bay | Dr. Adeel Khan
The Jordan B. Peterson Podcast
Advantages of Epizomal Vector Gene Therapy for Sarcopenia
Epizomal vector gene therapy is non-integrating and does not pose risks to the genome like viruses. It does not require immunosuppressants and can be removed with tetracycline if needed. The therapy lasts one and a half to two years and can be repeated, unlike viral vectors. The therapy is being targeted for conditions like sarcopenia, the loss of muscle mass in older adults, which is a significant factor in aging and mortality. The therapy aims to increase levels of a naturally occurring peptide called fallestin to preserve muscle mass and promote anti-aging effects.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
